Daiwa SB Investments Ltd. Purchases 420 Shares of Zimmer Biomet Holdings Inc (ZBH)

Daiwa SB Investments Ltd. lifted its position in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 5.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,470 shares of the medical equipment provider’s stock after acquiring an additional 420 shares during the quarter. Daiwa SB Investments Ltd.’s holdings in Zimmer Biomet were worth $1,022,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Private Advisor Group LLC raised its holdings in shares of Zimmer Biomet by 18.6% in the third quarter. Private Advisor Group LLC now owns 6,733 shares of the medical equipment provider’s stock valued at $791,000 after acquiring an additional 1,057 shares in the last quarter. Ingalls & Snyder LLC raised its holdings in shares of Zimmer Biomet by 2.6% in the third quarter. Ingalls & Snyder LLC now owns 19,675 shares of the medical equipment provider’s stock valued at $2,304,000 after acquiring an additional 507 shares in the last quarter. Koch Industries Inc. raised its holdings in shares of Zimmer Biomet by 49,697.3% in the second quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock valued at $1,033,000 after acquiring an additional 1,038,674 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in Zimmer Biomet by 10.0% in the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,444 shares of the medical equipment provider’s stock worth $1,925,000 after purchasing an additional 1,494 shares in the last quarter. Finally, WINTON GROUP Ltd bought a new position in Zimmer Biomet in the third quarter worth about $370,000. Hedge funds and other institutional investors own 85.92% of the company’s stock.

Zimmer Biomet Holdings Inc (NYSE ZBH) opened at $122.29 on Friday. Zimmer Biomet Holdings Inc has a fifty-two week low of $108.03 and a fifty-two week high of $133.49. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88. The stock has a market cap of $24,760.00, a PE ratio of 38.10, a PEG ratio of 1.96 and a beta of 1.15.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet had a net margin of 5.43% and a return on equity of 3.82%. The company had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.83 billion. During the same quarter last year, the company earned $1.79 EPS. The business’s revenue was down .8% compared to the same quarter last year. sell-side analysts forecast that Zimmer Biomet Holdings Inc will post 8.03 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 29th. Stockholders of record on Friday, December 29th will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $0.96 annualized dividend and a dividend yield of 0.79%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 29.91%.

ZBH has been the subject of a number of recent research reports. Royal Bank of Canada reduced their target price on shares of Zimmer Biomet to $125.00 and set an “outperform” rating for the company in a report on Tuesday, November 7th. SunTrust Banks set a $136.00 target price on shares of Zimmer Biomet and gave the stock a “buy” rating in a report on Wednesday, November 1st. Morgan Stanley reduced their target price on shares of Zimmer Biomet from $146.00 to $136.00 and set an “overweight” rating for the company in a report on Thursday, November 2nd. BMO Capital Markets reduced their target price on shares of Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating for the company in a report on Thursday, November 2nd. Finally, Deutsche Bank upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 target price for the company in a report on Tuesday, November 14th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $137.42.

ILLEGAL ACTIVITY WARNING: “Daiwa SB Investments Ltd. Purchases 420 Shares of Zimmer Biomet Holdings Inc (ZBH)” was originally published by Markets Daily and is the property of of Markets Daily. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.themarketsdaily.com/2018/01/12/daiwa-sb-investments-ltd-purchases-420-shares-of-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply